These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38043017)

  • 1. Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort.
    Pfrimmer C; Smitka M; Muschol N; Husain RA; Huemer M; Hennermann JB; Schuler R; Hahn A
    J Neuromuscul Dis; 2024; 11(1):167-177. PubMed ID: 38043017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M; Zhang L; Quan S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients.
    Poelman E; van den Dorpel JJA; Hoogeveen-Westerveld M; van den Hout JMP; van der Giessen LJ; van der Beek NAME; Pijnappel WWMP; van der Ploeg AT
    J Inherit Metab Dis; 2020 Nov; 43(6):1243-1253. PubMed ID: 32506446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.
    Kazi ZB; Desai AK; Troxler RB; Kronn D; Packman S; Sabbadini M; Rizzo WB; Scherer K; Abdul-Rahman O; Tanpaiboon P; Nampoothiri S; Gupta N; Feigenbaum A; Niyazov DM; Sherry L; Segel R; McVie-Wylie A; Sung C; Joseph AM; Richards S; Kishnani PS
    Genet Med; 2019 Apr; 21(4):887-895. PubMed ID: 30214072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of 64 children with classical infantile-onset Pompe disease since 2004: A French real-life observational study.
    Tardieu M; Cudejko C; Cano A; Hoebeke C; Bernoux D; Goetz V; Pichard S; Brassier A; Schiff M; Feillet F; Rollier P; Mention K; Dobbelaere D; Fouilhoux A; Espil-Taris C; Eyer D; Huet F; Walther-Louvier U; Barth M; Chevret L; Kuster A; Lefranc J; Neveu J; Pitelet G; Ropars J; Rivier F; Roubertie A; Touati G; Vanhulle C; Tardieu E; Caillaud C; Froissart R; Champeaux M; Labarthe F; Chabrol B
    Eur J Neurol; 2023 Sep; 30(9):2828-2837. PubMed ID: 37235686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences.
    Chien YH; Tsai WH; Chang CL; Chiu PC; Chou YY; Tsai FJ; Wong SL; Lee NC; Hwu WL
    Mol Genet Metab Rep; 2020 Jun; 23():100591. PubMed ID: 32373469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.
    Ebbink BJ; Aarsen FK; van Gelder CM; van den Hout JM; Weisglas-Kuperus N; Jaeken J; Lequin MH; Arts WF; van der Ploeg AT
    Neurology; 2012 May; 78(19):1512-8. PubMed ID: 22539577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The earliest enzyme replacement for infantile-onset Pompe disease in Japan.
    Tocan V; Mushimoto Y; Kojima-Ishii K; Matsuda A; Toda N; Toyomura D; Hirata Y; Sanefuji M; Sawada T; Sakai Y; Nakamura K; Ohga S
    Pediatr Int; 2022 Jan; 64(1):e15286. PubMed ID: 36074069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical immunologic response in a patient with CRIM-negative Pompe disease.
    Abbott MA; Prater SN; Banugaria SG; Richards SM; Young SP; Rosenberg AS; Kishnani PS
    Mol Genet Metab; 2011 Dec; 104(4):583-6. PubMed ID: 21889385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme.
    Yang CF; Liao TE; Chu YL; Chen LZ; Huang LY; Yang TF; Ho HC; Kao SM; Niu DM
    J Med Genet; 2023 May; 60(5):430-439. PubMed ID: 36137614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
    Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
    Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation.
    Curelaru S; Desai AK; Fink D; Zehavi Y; Kishnani PS; Spiegel R
    Mol Genet Metab Rep; 2022 Sep; 32():100893. PubMed ID: 35813979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: A longitudinal follow-up.
    Spiridigliozzi GA; Keeling LA; Stefanescu M; Li C; Austin S; Kishnani PS
    Mol Genet Metab; 2017 Jun; 121(2):127-137. PubMed ID: 28495044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: A case series.
    ElMallah MK; Desai AK; Nading EB; DeArmey S; Kravitz RM; Kishnani PS
    Pediatr Pulmonol; 2020 Mar; 55(3):674-681. PubMed ID: 31899940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early higher dosage of alglucosidase alpha in classic Pompe disease.
    Spada M; Pagliardini V; Ricci F; Biamino E; Mongini T; Porta F
    J Pediatr Endocrinol Metab; 2018 Dec; 31(12):1343-1347. PubMed ID: 30433875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.